P2736 - Gastroparesis as a Paraneoplastic Syndrome : A Comprehensive Review

Jayasree Ravilla, MD¹, Mahrukh Khan, MD¹, Siva Naga Srinivas Yarrarapu, MD¹, Harshavardhan Sanekommu, MD², Sobaan Taj, MD², Andrew Kruger, MD^1
1Monmouth Medical Center/RWJBH, Long Branch, NJ; ²Hackensack Meridian Jersey Shore University Medical Center, Neptune, NJ

Introduction: Gastroparesis is characterized by delayed gastric emptying without any mechanical blockages. Common causes are diabetes, post-surgical complications, and idiopathic factors but certain paraneoplastic diseases are also associated with gastroparesis. Cases of paraneoplastic gastroparesis have been reported in the literature and are linked to the presence of autoantibodies. In our study, we estimated the real magnitude, prevalence, demographics, and prognostic value of paraneoplastic gastroparesis.

Methods: We summarized and analyzed the data statistically after collecting and reviewing cases worldwide that reported paraneoplastic gastroparesis.

Results: We studied a total of 18 cases of paraneoplastic gastroparesis reported in the literature. The median age of prevalence is 62.3 years (figure 1). The incidence was higher in Males compared to Females (55.6% vs 44.4%, respectively) (figure 2). The prevalence was highest in small cell lung cancer (SCLC) (44%) followed by non-SCLC and thymoma (11.11%) (table 1). Patients commonly presented with nausea, post-prandial vomiting, bloating, and weight loss. Symptoms occurred early in 88.8% of the cases. There was complete resolution of the symptoms in 12 patients (66.66%) due to intervention, and 3 cases (16.66%) died due to chemotherapy-related complications. Out of 12 cases, 6(50%) patients underwent only chemotherapy, 16.66 % got immunoglobulin therapy and 16.66% underwent surgery. Out of 18, 4 patients belonged to white, caucasian, African, and Japanese but there was no data on races for the remaining cases.

Discussion: Paraneoplastic gastroparesis is underdiagnosed as physicians tend to overlook the association with malignancies. Paraneoplastic gastroparesis is associated with certain antibodies like ANNA-1 and P/Q type calcium channel antibodies which can target the enteric neurons. Treatment is targeting the underlying malignancy responsible for the symptoms.



Disclosures:


Jayasree Ravilla, MD¹, Mahrukh Khan, MD¹, Siva Naga Srinivas Yarrarapu, MD¹, Harshavardhan Sanekommu, MD², Sobaan Taj, MD², Andrew Kruger, MD¹. P2736 - Gastroparesis as a Paraneoplastic Syndrome : A Comprehensive Review, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.